The brief
- A big 2023 trial showed semaglutide cut heart attacks, strokes and heart deaths by 20% in people with obesity and heart disease.
- FDA approved the Wegovy pill in Dec 2025; US launch on 5 Jan 2026.
- CagriSema gave 22.7% weight loss in Phase 3, below the 25% Novo hoped for; now under FDA review.
Programs
Novo Nordisk, two programs
Updated 20 Mar 2026Wegovy (semaglutide)Semaglutide, a long-lasting copy of the GLP-1 hormone. Weekly shots give about 15% average weight loss; the pill version has a helper that gets it through the stomach.ScalingUpdated 20 Mar 2026View program →CagriSemaA weekly shot combining semaglutide with cagrilintide, a copy of another fullness hormone (amylin).DeployNextFDA decision · 2026Updated 1 Jun 2025View program →
Research · Proto · Pilot · Deploy · Scaling
Peers
Company & funding
- Listed
- NVO (opens google.com)NYSE
- HQ
- DK
- Founded
- 1923